Key Developments: CSL Ltd (CSL.AX)

CSL.AX on Australia Stock Exchange

16 Sep 2014
Price Change (% chg)

$-0.62 (-0.85%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Search Stocks

Latest Key Developments (Source: Significant Developments)

CSL Ltd reaffirms FY 2014 guidance
Tuesday, 11 Feb 2014 07:00pm EST 

CSL Ltd:Reaffirms fiscal 2014 guidance.Reaffirms fiscal 2014 7 pct. NPAT at constant currency.EBIT growth at 10 pct. at constant currency and expect that its earnings per share (EPS) will exceed NPAT growth driven by its capital management plans and activities that the company have in base.Reported net income of $1.234 billion, EBIT of $1.510 billion and EPS of $2.48 in fiscal 2013.Fiscal 2014 net income of $1.324 billion, EBIT of $1.689 billion and EPS of $2.75 - Thomson Reuters I/B/E/S.  Full Article

Kcentra, from CSL Ltd's CSL Behring, receives FDA approval for use in warfarin reversal in patients undergoing surgery
Friday, 13 Dec 2013 05:58pm EST 

CSL Ltd:Says CSL Behring Kcentra (Prothrombin Complex Concentrate [Human]) has received U.S. Food and Drug Administration (FDA) approval for an expanded indication urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist therapy in adult patients.Says Kcentra, approved by the FDA in April 2013 for the urgent reversal of warfarin therapy in adult patients with acute major bleeding, is the only non-activated 4-factor prothrombin complex concentrate (4F-PCC) indicated in the U.S. for these uses.  Full Article

CSL Ltd Announces Agreement To Settle U.S. Antitrust Class Action Litigation; Reaffirms FY 2014 NPAT Guidance
Sunday, 6 Oct 2013 05:32pm EDT 

CSL Ltd announced that it has signed an agreement to settle the U.S. antitrust class action litigation, filed by certain U.S. and Puerto Rican hospital groups, which has been ongoing since 2009. The settlement agreement resolves and dismisses all claims and potential claims of class members against CSL in the lawsuit, as well as those against the Plasma Protein Therapeutics Association, an industry trade association. The settlement, including payment of USD64 million, is subject to an approval process by the U.S. federal court. This process is expected to take several months during which time CSL’s involvement in the litigation will be on hold. The Company continues to anticipate fiscal 2014 net profit after tax (NPAT) growth in line with the guidance provided at the Company's full year result announced on August 14, 2013, subject to the announcement regarding the settlement of the U.S. antitrust litigation. If approved, the settlement represents a one-off charge reducing NPAT expectations for fiscal 2014 by USD39 million. According to I/B/E/S Estimates, analysts on an average are expecting the Company to report net income of USD1.346 billion for fiscal 2014.  Full Article

CSL Ltd Recommends Final Dividend
Thursday, 12 Sep 2013 08:59pm EDT 

CSL Ltd announced that the Directors have recommended the payment of a final dividend of USD0.52 per share, unfranked (2012: ordinary dividend of AUD0.47 per share, unfranked). The final dividend id expected to be paid on October 4, 2013.  Full Article

CSL Ltd Announces Terms Of Departure Of Managing Director And CEO
Thursday, 27 Jun 2013 09:33pm EDT 

CSL Ltd announced that it previously announced that Dr Brian McNamee will be succeeded by Mr Paul Perreault as Managing Director and Chief Executive Officer of CSL from July 01, 2013. Dr McNamee has worked collaboratively with the Board and his successor Mr Perreault over an extended period to ensure a smooth transition in the best interests of the Company. This includes Dr McNamee's agreement to remain available to the Company during the period July 01, to October 15, 2013.  Full Article

CSL Ltd Closes New USD500 Million Private Placement
Wednesday, 27 Mar 2013 06:18pm EDT 

CSL Ltd announced that on March 27, 2013 it closed a new USD500 million Private Placement in the US. The Private Placement consists of four maturities, as follows: USD100 million for 5 years bullet with coupon value 2.07%; USD150 million for 7 years bullet with coupon value 2.57%; USD150 million for 10 years bullet with coupon value 3.20%; USD100 million for 12 years bullet with coupon value 3.32%. The Private Placement has a weighted average interest rate of 2.81% and average life of 8.5 years. The proceeds from the Private Placement will be used to fund the Group’s capital management plan, including on-market buybacks, and for general corporate purposes.  Full Article

CSL Ltd Announces H1 2013 Interim Dividend
Tuesday, 12 Feb 2013 05:29pm EST 

CSL Limited announced the proposed interim dividend of USD 0.50, expected to be paid on April 5, 2013 out of retained earnings at 31 December 2012.  Full Article

CSL Ltd Raises FY 2013 Profit Guidance
Monday, 26 Nov 2012 04:47pm EST 

CSL Ltd announced a revised USD profit outlook for fiscal 2013. The Company now expects net profit after tax to grow by approximately 20% at constant currency, despite competitive business conditions. In August 2012, the Company reported a net profit after tax of USD 1,024 million and provided guidance that it expected profit to grow approximately 12% during fiscal 2013.  Full Article

Australia shares seen slipping, but greenback rise may buoy exporters

MELBOURNE, Sept 10 - Australian shares are set to open lower on Wednesday after Wall Street fell, but a rise in the U.S. dollar may shore up the market's biggest exporters, like the miners, blood products maker CSL and packaging group Amcor. * Local share price index futures fell 0.3 percent to 5,586.0, which was a 21.9-point discount to the underlying S&P/ASX 200 index close. The benchmark rose 0.5 percent on Tuesday. * New Zealand's benchmark NZX 50 index slipped 0.2

Search Stocks